Biopharmx Corp (NYSEAMERICAN:BPMX) Director Stephen Morlock sold 1,125,027 shares of Biopharmx stock in a transaction that occurred on Monday, October 22nd. The stock was sold at an average price of $0.18, for a total value of $202,504.86. The sale was disclosed in a document filed with the SEC, which is accessible through this link.
BPMX stock traded down $0.01 during midday trading on Monday, hitting $0.17. The stock had a trading volume of 3,364,500 shares, compared to its average volume of 7,667,573. Biopharmx Corp has a 12-month low of $0.10 and a 12-month high of $0.38.
Biopharmx (NYSEAMERICAN:BPMX) last released its earnings results on Thursday, August 30th. The biotechnology company reported ($0.02) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.02). The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.02 million.
Biopharmx Company Profile
BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC).
See Also: How to Invest in an Index Fund
Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with MarketBeat.com's FREE daily email newsletter.